ANNUAL MEETING

OCTOBER 26 – 28, 2014

ASSOCIATION OF
AMERICAN CANCER INSTITUTES

CME provided jointly by the American Association for Cancer Research and the Association of American Cancer Institutes.
The cancer centers represented by the Association of American Cancer Institutes (AACI) form America’s cancer research infrastructure and are the hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2014 AACI/CCAF Annual Meeting.

This event convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation’s cancer centers, and provides them with a forum to discuss common issues. The gathering also afford an opportunity to acknowledge scientific leaders and individuals in public service who help to advance and promote cancer research.

This year, a distinguished panel of past and current cancer center directors and administrators will provide their perspectives on the evolution of cancer centers. The meeting also features discussions on emerging models for research and clinical care, tobacco use reduction, molecular data interpretation, and the human papillomavirus vaccine. In addition, incoming AACI President Dr. George Weiner will talk about his AACI Presidential Initiative, “The Academic Difference.”

In the public policy arena, speakers will consider the changing landscape of clinical research, the current political environment and the upcoming midterm elections.
Program Committee

2014 AACI/CCAF Annual Meeting Program Committee Members

**Chair:** Robert S. DiPaola, MD  
Rutgers Cancer Institute of New Jersey

Dario C. Altieri, MD  
The Wistar Institute

Michael K. Benedict, PharmD  
GRU Cancer Center

Kevin J. Cullen, MD  
University of Maryland Marlene and Stewart Greenebaum Cancer Center

Lisa A. Damiani  
Roswell Park Cancer Institute

David M. Gosky, MA, MBA  
UK Markey Cancer Center

Dina G. Halme, PhD  
University of Virginia Cancer Center

Shreya Kanodia, PhD  
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center

Michelle M. Le Beau, PhD  
The University of Chicago Comprehensive Cancer Center

Patrick J. Loehrer, Sr., MD  
Indiana University Melvin and Bren Simon Cancer Center

Barbara Duffy Stewart, MPH  
Association of American Cancer Institutes

Donald L. Trump, MD, FACP  
Roswell Park Cancer Institute

George J. Weiner, MD  
Holden Comprehensive Cancer Center, University of Iowa

Agenda

Sunday, October 26

**11:00 am**  
Registration Begins  
Grand Court, River II Level

**11:00 am**  
Exhibits Open  
Grand Court, River II Level

**12:30 pm**  
Welcome and Business Meeting  
President’s Report  
Dr. Michelle M. Le Beau  
The University of Chicago Comprehensive Cancer Center

Executive Director’s Report  
Ms. Barbara Duffy Stewart  
Association of American Cancer Institutes

Treasurer’s Report  
Ms. Dorothy Puhy  
Dana-Farber Cancer Institute  
Harvard Medical School

Program Chair’s Report  
Dr. Robert S. DiPaola  
Rutgers Cancer Institute of New Jersey

CCAF Report  
Dr. Michael K. Benedict  
GRU Cancer Center

**1:15 pm**  
The Evolution of Cancer Centers: Looking Back, Looking Ahead  
Moderator: Dr. H. Shelton Earp, III  
UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

The Birth of the Cancer Centers Program  
Dr. Robert C. Young  
RCY Medicine

Cancer Centers: Past and Future  
Dr. Joseph Simone  
Simone Consulting

The Matrix Cancer Center- Rising Tide or Disruptive Innovator?  
Ms. Marcy Waldinger  
University of Michigan Comprehensive Cancer Center

All 2014 AACI/CCAF Annual meeting sessions will be held in Grand Ballroom, River II Level, except where indicated.
### Sunday, October 26 continued

**Rutgers Cancer Institute: Optimization of a Matrix Structure Within a University**  
Dr. Robert S. DiPaola  
*Rutgers Cancer Institute of New Jersey*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 pm</td>
<td><strong>Break</strong></td>
</tr>
</tbody>
</table>

**Opportunities to Transform the Delivery of Complex Care: Cost and Utilization Differences at an Academic Medical Center vs. a Community Hospital**  
Ms. Erika Johnson  
*University HealthSystem Consortium*  
Mr. Neal Peyser  
*University HealthSystem Consortium*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 2:30 pm | **2:30 pm**  
*Opportunities to Transform the Delivery of Complex Care: Cost and Utilization Differences at an Academic Medical Center vs. a Community Hospital*  
Ms. Erika Johnson  
*University HealthSystem Consortium*  
Mr. Neal Peyser  
*University HealthSystem Consortium* |

**The Academic Difference: The Central Role of Cancer Centers in Patient Care and Research**  
Dr. George J. Weiner  
*Holden Comprehensive Cancer Center*  
University of Iowa

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 3:30 pm | **3:30 pm**  
*The Academic Difference: The Central Role of Cancer Centers in Patient Care and Research*  
Dr. George J. Weiner  
*Holden Comprehensive Cancer Center*  
University of Iowa |

**Sessions End**

**CCAF Business Meeting**  
(Closed session for members of CCAF)

**AACI Physician Clinical Leadership Initiative**  
(Promenade Ballroom B, River Level II — closed session)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 4:00 pm | **4:00 pm**  
*CCAF Business Meeting*  
(Closed session for members of CCAF)  
*AACI Physician Clinical Leadership Initiative*  
(Promenade Ballroom B, River Level II — closed session) |

**Welcome Reception**  
(Grand Court, River II Level)

### Monday, October 27

**7:00 am**  
**Continental Breakfast**  
(Promenade Ballroom, River II Level)

**7:00 am**  
**Exhibits Open**  
(Grand Court, River II Level)

**8:00 am**  
**Emerging Models for Research and Clinical Care in Cancer Centers**  
Moderator: Dr. Robert S. DiPaola  
*Rutgers Cancer Institute of New Jersey*

**Bringing Cancer Research to the Community: The Wistar-Helen Graham Experience**  
Dr. Dario C. Altieri  
*The Wistar Institute*

**Models of Collaborative Partnership: An Indiana Perspective**  
Dr. Patrick J. Loehrer  
*Indiana University Melvin and Bren Simon Cancer Center*

**Development of the MD Anderson Cancer Network: Challenges and Opportunities**  
Dr. Merrill S. Kies  
*The University of Texas MD Anderson Cancer Center*

**9:00 am**  
**AACI Government Relations Forum**  
(Grant Lincoln Room, River I Level — closed session)

**9:15 am**  
**The Best of the 2014 Annual AACI Clinical Research Initiative Meeting**  
Moderator: Ms. Rhoda Arzoomanian  
Yale Cancer Center  
Yale University School of Medicine

**Precision Oncology and its Impact on Clinical Research: Perspectives from Payers and Policy Considerations**  
Dr. Tony Reid  
*UC San Diego Moores Cancer Center*
Monday, October 27 continued

Conducting Cancer Clinical Trials in the Era of Value-Based Reimbursement
Dr. Randall F. Holcombe
Mount Sinai Health System
Tisch Cancer Institute

Financing Clinical Trial Offices: A Slippery Slope
Dr. Kirsten Erickson
University of Kansas Cancer Center

Speeding-Up the Drug Discovery Process: Update on the AACI Corporate Roundtable Working Group
Mr. Nick Fisher
Siteman Cancer Center

Mr. Dan Davis
Eli Lilly and Company

10:15 am  Break
10:30 am  Distinguished Scientist Presentation
The AML Genome(s)
Dr. Timothy J. Ley
The Genome Institute
Siteman Cancer Center
Barnes-Jewish Hospital at Washington University School of Medicine

11:30 am  Awards Luncheon (Promenade Ballroom, River II Level)

2014 AACI Distinguished Public Service Award
The Honorable Richard Durbin (D-IL)

2014 AACI Distinguished Public Service Award
The Honorable Michael McCaul (R-TX)

12:30 pm  AACI Translational Cancer Research Fellowship Poster Presentations (Grand Court, River II Level)

Imaging Hypoxia in Lung Cancer
Dr. Olya Grove
Moffitt Cancer Center

Monday, October 27 continued

Does Spry Expression Confer Sensitivity to RAF Inhibitors in BRAF V600E Tumors?
Dr. Piro Lito
Memorial Sloan Kettering Cancer Center

1:00 pm  The Political Environment and the Midterm Elections
Mr. Ross A. Frommer
Herbert Irving Comprehensive Cancer Center
Columbia University

1:45 pm  The Changing Landscape of Clinical Research
Moderator: Dr. Patrick J. Loehrer
Indiana University Melvin and Bren Simon Cancer Center

The Role of Implementation Science in Accelerating Clinical Research
Ms. Nadia M. Adams
Indiana University Melvin and Bren Simon Cancer Center

New Trial Designs and Their Impact on Clinical Research
Dr. Monica M. Bertagnolli
Harvard Medical School
Brigham and Women’s Hospital

The Outlook for National Institutes of Health (NIH) Funding
Mr. Erik Fatemi
Cornerstone Government Affairs

2:45 pm  Role of Cancer Centers in Accelerating HPV Vaccine Uptake
Dr. Melinda Wharton
National Center for Immunization & Respiratory Diseases
Centers for Disease Control & Prevention

3:15 pm  Break

Program Subject to Change
### Monday, October 27 continued

**3:30 pm**  
**Concurrent Sessions**

- **Interpretation of Molecular Data**  
  (Astor Ballroom, River I Level)  
  **Moderator:** Dr. Michelle M. Le Beau  
  The University of Chicago Comprehensive Cancer Center

- **Shifting Landscape of the Cancer Center Support Grant (CCSG) Submission**  
  (Grand Ballroom, River II Level)  
  **The Duke Cancer Institute CCSG Experience**  
  **Moderator:** Ms. Leigh A. Burgess  
  Duke Cancer Institute Duke University Medical Center

- **Defining “Actionable Mutations” and How Best to Act on Them**  
  Dr. Keith T. Flaherty  
  Massachusetts General Hospital Cancer Center

- **Interpretation of Molecular Data: Tower of Babel?**  
  Dr. Stanley R. Hamilton  
  The University of Texas MD Anderson Cancer Center

- **Systematic Elucidation and Targeting of Non-Oncogene Dependencies: A New Twist on Precision Cancer Medicine**  
  Dr. Andrea Califano  
  Herbert Irving Comprehensive Cancer Center Columbia University

### Tuesday, October 28

**7:00 am**  
**Concurrent Breakfast Roundtable Discussions**  
(Astor Ballroom, River I Level)

- **Submitting a CCSG Application**
  **Pre-Submission Tasks and Recommended Deadlines**  
  Dr. Maryann Donovan  
  University of Pittsburgh Cancer Institute  
  UPMC CancerCenter

- **Submitting Electronically Using ASSIST**  
  Ms. Lauren Hackett  
  Vanderbilt-Ingram Cancer Center

- **Site Visit – How to Plan for it and What to Expect**  
  Mr. Robert Gerlach  
  Dartmouth-Hitchcock Norris Cotton Cancer Center

### Monday, October 27 continued

**5:00 pm**  
**Sessions End**

**8:30 – 11:00 pm**  
**Hospitality Suite** (Ember Grille, Lobby Level)

**7:00 am**  
**Continental Breakfast** (Promenade Ballroom, River II Level)

**7:00 am**

- **Exhibits Open** (Grand Court, River II Level)

**8:00 am**

- **Tamping Down Tobacco Use: Past Successes, Present Challenges and Preparations for the Future**  
  **Moderator:** Dr. Robert T. Croyle  
  Division of Cancer Control and Population Sciences National Cancer Institute

- **The Epidemiology of Tobacco Use in the United States: Key Findings from the 50th Anniversary of The Surgeon General’s Report on Tobacco**  
  Dr. Cristine D. Delnevo  
  Rutgers Cancer Institute of New Jersey
Role of Electronic Cigarettes in Cancer Prevention  
**Dr. Maciej L. Goniewicz**  
Roswell Park Cancer Institute

Tobacco Use and Cessation Among Cancer Patients  
**Dr. Stephanie R. Land**  
Tobacco Control Research Branch  
National Cancer Institute

Strategies to Implement Tobacco Cessation Treatment into Cancer Centers  
**Dr. Benjamin A. Toll**  
Yale Cancer Center  
Yale University School of Medicine

MD Anderson’s EndTobacco Program  
**Dr. Ernie Hawk**  
University of Texas MD Anderson Cancer Center

9:30 am  **Break**

9:45 am  **Community Impact and Disparities**  
**Moderator: Dr. George J. Weiner**  
Holden Comprehensive Cancer Center  
University of Iowa

Racial/Ethnic Cancer Health Disparities: How Did We Get Here and How Can We Eliminate It?  
**Dr. Willie Underwood**  
Roswell Park Cancer Institute

Planting Seedlings: Growing Research from Community Engagement  
**Dr. Karen E. Kim**  
The University of Chicago Comprehensive Cancer Center

Factors Influencing Patient Pathways for Receipt of Cancer Care at an NCI-Designated Cancer Center  
**Dr. Deborah Erwin**  
Roswell Park Cancer Institute

Teledmedicine - Swimming into the Mainstream  
**Dr. Karen Rheuban**  
University of Virginia Cancer Center

**Tuesday, October 28 continued**

Cancer Control Partnerships: Working Together to Reduce Health Disparities  
**Ms. Tina Devery**  
Iowa Cancer Consortium

11:15 am  **Update on the Cancer Centers Program**  
**Dr. Linda K. Weiss**  
National Cancer Institute

12:15 pm  **Adjourn**
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

• Evidence-based strategies for success in improving public health
• The new rules and guidelines for the conduct of clinical research developed in response to the ACA
• Effective models for reducing disparities in health, cancer prevention and the delivery of cancer care
• The history of tobacco use in the United States and the potential impact of e-cigarettes on public health
• The evolution of the NCI-designated cancer center program and the opportunities and challenges the program faces in the future
• New insights about mapping genetic mutations to identify targeted therapies for future cancer treatments
• Transformative business models for cancer centers
• The impact of the genomic revolution on the cancer center
• The effectiveness of a multi-disciplinary environment in facilitating translational medicine
• NCI’s programmatic priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to the nation’s cancer centers

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvay at 412-605-1476 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s 93 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care in the U.S. Medical professionals from across the U.S., including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer attend this meeting.

Program Subject to Change
CME approval granted January 29, 2014

CME approval granted January 29, 2014
Awardee Profiles

2014 Distinguished Scientist Award

**Dr. Timothy J. Ley**  
The Genome Institute  
Siteman Cancer Center  
Barnes-Jewish Hospital at Washington University School of Medicine

Timothy J. Ley, MD, is the Lewis T. and Rosalind B. Apple Chair in Oncology at Washington University. He serves as director of the stem cell biology section in the Department of Medicine, associate director of The Genome Institute, and is a member of Siteman Cancer Center.

Dr. Ley is a past president of the American Society for Clinical Investigation, past treasurer of the American Association of Physicians, a fellow of the American Academy of Arts and Sciences, and a member of the Institute of Medicine. He was the 2012 recipient of the E. Donnall Thomas Prize from the American Society of Hematology.

Dr. Ley led the team at Washington University in St. Louis that sequenced the first human cancer genomes, and he is principal investigator on a recently awarded five-year, $14.3 million National Institutes of Health Program Project Grant in leukemia.

He has developed approaches to reactivate fetal hemoglobin synthesis for patients with hemoglobinopathies, defined the role of the perforin/granzyme system for the function of cytotoxic and regulatory T cells, and has performed pioneering studies that have defined the genomics of AML. He has also written extensively about the physician-scientist career path, and was a key advocate for establishing the extramural Loan Repayment Programs at the NIH. He has mentored more than 50 pre- and post-doctoral fellows in his laboratory; most hold research positions in academic medicine or pharmaceutical companies.

Dr. Ley received his BA from Drake University, his MD from Washington University School of Medicine, and performed his internal medicine residency at Massachusetts General Hospital. He completed fellowships in Hematology and Oncology at the NIH and at Washington University, and joined the faculty at Washington University in St. Louis in 1986.

The AACI Distinguished Scientist Award acknowledges extraordinary scientific accomplishments and contributions to cancer research. Previous honorees are Drs. Brian Druker, Lee Hartwell, Mary Claire King, Janet Rowley, Stuart Schreiber, Margaret R. Spitz, Bert Vogelstein, Robert Weinberg and Irving Weissman.

2014 AACI Distinguished Public Service Awards

**The Honorable Richard Durbin**  
United States Senate

AACI recognizes U.S. Senator Richard Durbin (D-IL) with its 2014 Distinguished Public Service Award for his outstanding record of support for biomedical research.

Senator Durbin has served as a member of the Senate Cancer Coalition and is a dedicated advocate for prevention efforts, concentrating much of his career on legislative efforts to curb tobacco use. Senator Durbin has remained committed to supporting robust funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) throughout his tenure in Congress.

Senator Durbin serves as the Assistant Majority Leader—also known as the Majority Whip, the second highest ranking position in the Senate. He was elected to the U.S. Senate on November 5, 1996, and re-elected in 2002 and 2008.

**The Honorable Michael McCaul**  
United States House of Representatives

AACI recognizes U.S. Representative Michael McCaul (R-TX) with its 2014 Distinguished Public Service Award for his dedicated efforts on behalf of cancer patients and medical research.

Representative McCaul is a co-chair and founder of the Congressional Childhood Cancer Caucus and is a member of the House Cancer Caucus. Representative McCaul has worked tirelessly to advance the childhood cancer agenda on Capitol Hill and has developed strong relationships with cancer centers in his home state of Texas and with the cancer community at large. In the 112th Congress, Congressman McCaul’s legislation, the Creating Hope Act, was signed by President Obama and became law in October 2012, creating incentives for pharmaceutical companies to create new treatments for pediatric cancer patients.

Congressman McCaul is currently serving his fifth term representing Texas’ 10th District, which stretches from Austin to the Houston suburbs.
Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- Huron Consulting Group
- Pfizer

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Celgene
- Essex Management
- Genentech
- Gilead
- Lilly
- Merck
- Millennium
- Velos
- WIRB-Copernicus Group

Support as of October 13, 2014

Exhibitors

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

iLab Solutions, LLC

iLab Solutions is the leading provider of core facility management solutions to academic research institutions. In March 2013 iLab signed a partnership with Vanderbilt University CORES. This partnership brings together the two most sophisticated and broadly-used solutions for core facility management serving over 1,000 core facilities at more than 100 research institutions, including 30 of the top 50 recipients of NIH funding and 27 NCI-designated cancer centers. iLab has extensive experience providing enterprise-level solutions. These solutions include institutional financial systems (e.g., SAP, Oracle, PeopleSoft, Lawson, Banner, IFAS, etc.) and identity management systems (e.g., Active Directory and Shibboleth).

www.ilabsolutions.com

Intellisphere

Intellisphere is a leading provider of healthcare publishing, research, information, and education for the medical industry. Our company serves the needs of hundreds of thousands of general practitioners, specialists, patients, nurses, pharmacists, and managed care professionals through an extensive suite of magazines, journals, e-mail databases, websites, events, and personal meetings. We strive to inform and educate oncology professionals and patients with the latest clinically relevant news and insights through our OncLive® and CURE Media Group publications and website. Through our Strategic Alliance Partnership program, we are able to promote the research innovation and outreach programs of the leading cancer centers and oncology nursing programs across the country. The partnerships provide our audience with direct access to important research, clinical trial initiatives, and clinical practice news that are ongoing at these institutions.

Precision Imaging Metrics

Precision Imaging Metrics helps cancer centers across the country produce higher-quality and timelier imaging data, enhancing clinical trials and patient care. In 2004, Drs. Gordon Harris and Annick Van den Abbeele founded the Tumor Imaging Metrics Core (TIMC) at the Dana Farber / Harvard Cancer Center (DF/HCC). Since its inception, TIMC has analyzed over 45,000 scans for almost 1000 clinical trials. This vast experience is the foundation on which Precision Imaging Metrics – and its flagship Metrics Manager application – has been built. The Metrics Manager application is currently in use by DF/HCC, Yale Cancer Center, and Fred Hutchinson Cancer Research Center at the University of Washington and scheduled to be deployed this fall at the Huntsman Cancer Institute at the University of Utah.
## Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

### Disclosure of Financial Relationships

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Affiliation</th>
<th>Relationships</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adams</td>
<td>Nadia</td>
<td>Indiana University Melvin and Bren Simon Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Allman</td>
<td>Diane</td>
<td>The Wistar Institute</td>
<td>No Relationships</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Arzooomanian</td>
<td>Rhoda</td>
<td>Yale Cancer Center, Yale University School of Medicine</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Benedict</td>
<td>Michael</td>
<td>GRU Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
</tr>
<tr>
<td>Bertagnolli</td>
<td>Monica</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bumpus</td>
<td>Leigh</td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Caliano</td>
<td>Andrea</td>
<td>Herbert Irving Comprehensive Cancer Center, Columbia University</td>
<td>Dow Agro Sciences</td>
<td>Speaker</td>
</tr>
<tr>
<td>Corley</td>
<td>Barbara</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Croyle</td>
<td>Robert</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Cullen</td>
<td>Kevin</td>
<td>University of Maryland Marlene and Stewart Greenebaum Cancer Center</td>
<td>Allergan Pharmaceutical, Bristol Myers Squibb, Covance, liaVita Inc., Intuitive Surgical, Merck &amp; Co., Millipore Corp.</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Damani</td>
<td>Lisa</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Davis</td>
<td>Daniel</td>
<td>Eli Lilly &amp; Company</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>DeLeo</td>
<td>Cristine</td>
<td>Rutgers Cancer Institute of New Jersey</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Deersey</td>
<td>Tina</td>
<td>Holden Comprehensive Cancer Center, University of Iowa</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>DiPaola</td>
<td>Robert</td>
<td>Rutgers Cancer Institute of New Jersey</td>
<td>No Relationships</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Donovan</td>
<td>Maryann</td>
<td>University of Pittsburgh Cancer Institute, UPMC Cancer Centers</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dorer</td>
<td>Marion</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Eap</td>
<td>H. Shelton</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>Merixs, Inc.</td>
<td>Speaker</td>
</tr>
<tr>
<td>Erickson</td>
<td>Kristen</td>
<td>University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Erwin</td>
<td>Deborah</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Falters</td>
<td>Erik</td>
<td>Cornerstone Government Affairs</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Felsher</td>
<td>Nicholas</td>
<td>Siteman Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Fishbery</td>
<td>Keith</td>
<td>Massachusetts General Hospital</td>
<td>RocheGenerentech, GiaoxSmithKline, Novartis</td>
<td>Speaker</td>
</tr>
<tr>
<td>Frommer</td>
<td>Ross</td>
<td>Herbert Irving Comprehensive Cancer Center, Columbia University</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Gerfach</td>
<td>Robert</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Gomewicz</td>
<td>Marcie</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Gosky</td>
<td>David</td>
<td>UK Markey Cancer Center</td>
<td>Pfizer</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hackett</td>
<td>Lauren</td>
<td>Vanderbilt Ingram Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Halme</td>
<td>Dina</td>
<td>University of Virginia Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hamilton</td>
<td>Stanley</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>Intervention Insights</td>
<td>Program Committee</td>
</tr>
<tr>
<td>Hawk</td>
<td>Ernest</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>Cancer Prevention Pharmaceuticals, FLx Pharma, Inc., Pozen, Inc., Cancer Prevention Pharmaceuticals, John Wiley &amp; Sons, United</td>
<td>Speaker</td>
</tr>
<tr>
<td>Holcombe</td>
<td>Randall</td>
<td>Mount Sinai Health System Tisch Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Johnson</td>
<td>Erika</td>
<td>University HealthSystem Consortium</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kanodia</td>
<td>Shreya</td>
<td>Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kies</td>
<td>Merit</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kim</td>
<td>Karen</td>
<td>The University of Chicago Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Land</td>
<td>Stephanie</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Le Beau</td>
<td>Michelle</td>
<td>The University of Chicago Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Levy</td>
<td>Timothy</td>
<td>Siteman Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Loehrer</td>
<td>Patrick</td>
<td>Indiana University Melvin and Bren Simon Cancer Center</td>
<td>Talo, Novartis</td>
<td>Speaker</td>
</tr>
<tr>
<td>Petrelli</td>
<td>Nicholas</td>
<td>Christiana Care Health System</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Peyster</td>
<td>Neal</td>
<td>University HealthSystem Consortium</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Red</td>
<td>Tony</td>
<td>UC San Diego Moores Cancer Center</td>
<td>Generentech, Novartis</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rheuban</td>
<td>Karen</td>
<td>University of Virginia Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Simoes</td>
<td>Joseph</td>
<td>Simon Consulting</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara Duffy</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee</td>
</tr>
<tr>
<td>Toll</td>
<td>Benjamin</td>
<td>Yale Cancer Center, Yale University School of Medicine</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Trump</td>
<td>Donald</td>
<td>Roswell Park Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Underwood</td>
<td>Willie</td>
<td>Roswell Park Cancer Institute</td>
<td>Janus Scientific</td>
<td>Speaker</td>
</tr>
<tr>
<td>Waldinger</td>
<td>Maryc</td>
<td>University of Michigan Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Weiner</td>
<td>George</td>
<td>Holden Comprehensive Cancer Center, University of Iowa</td>
<td>No Relationships</td>
<td>Speaker, Program Committee</td>
</tr>
<tr>
<td>Weiss</td>
<td>Linda</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wharton</td>
<td>Melinda</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
</tr>
<tr>
<td>Young</td>
<td>Robert</td>
<td>RCYMedicine</td>
<td>AVEO Pharmaceuticals, Inc., Teva, Pfizer, West Pharm Services, Merck, J&amp;J</td>
<td>Speaker</td>
</tr>
</tbody>
</table>

Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Shareholder, SB, Speakers’ Bureau, H, Honoraria, O, Other.